BMP9 signaling affects tumor cells, endothelial cells and pericytes in vitro. Anti-BMP9 therapy retards tumor growth in vivo. Ex vivo analysis reveals increased vascular coverage and reduced permeability. Precursor BMP9 and pro-domain levels are elevated in plasma of cancer patients.